Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Exclusion Criteria

• •1. Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator.
• •2. Inability to carry out pulmonary function testing.
• •3. A respiratory infection or exacerbation of COPD in the four weeks prior to screening.
• •4. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study
• •5. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.
• •6. Cancer or any other chronic disease with poor prognosis and/or affecting patient status.
• •7. A history of thoracotomy with pulmonary resection.
• •8. Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients.
• •9. History of alcohol or drug abuse.
• •10. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
• •11. Patients who received any investigational new drug within the last 4 weeks prior to the screening visit.
• •12. Patients treated with any non-permitted concomitant medication (see 7.2).